These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 10745525

  • 1. Readministration of abciximab in percutaneous coronary intervention.
    Fry ET.
    J Invasive Cardiol; 1999 Apr; 11(4):251-8. PubMed ID: 10745525
    [Abstract] [Full Text] [Related]

  • 2. Abciximab readministration.
    Orford JL, Holmes DR.
    Rev Cardiovasc Med; 2002 Apr; 3(2):67-70. PubMed ID: 12447149
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting.
    Merlini PA, Rossi M, Menozzi A, Buratti S, Brennan DM, Moliterno DJ, Topol EJ, Ardissino D.
    Circulation; 2004 May 11; 109(18):2203-6. PubMed ID: 15117843
    [Abstract] [Full Text] [Related]

  • 5. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention.
    Suleiman M, Gruberg L, Hammerman H, Aronson D, Halabi M, Goldberg A, Grenadier E, Boulus M, Markiewicz W, Beyar R.
    J Invasive Cardiol; 2003 Jun 11; 15(6):319-23. PubMed ID: 12777670
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
    Tcheng JE, Kandzari DE, Grines CL, Cox DA, Effron MB, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Mehran R, Stone GW, CADILLAC Investigators.
    Circulation; 2003 Sep 16; 108(11):1316-23. PubMed ID: 12939213
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The use of abciximab in coronary angioplasty--an Asian centre's experience.
    Tan HC, Lim YT, Lim TT, Cheng A, Chia BL.
    Singapore Med J; 2000 Feb 16; 41(2):69-73. PubMed ID: 11063206
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Acute profound thrombocytopenia without bleeding complications after re-administration of abciximab.
    Nguyen N, Salib H, Mascarenhas DA.
    J Invasive Cardiol; 2001 Jan 16; 13(1):56-8. PubMed ID: 11146690
    [Abstract] [Full Text] [Related]

  • 13. Readministration of abciximab: interim report of the ReoPro readministration registry.
    Tcheng JE, Kereiakes DJ, Braden GA, Jordan RE, Mascelli MA, Langrall MA, Effron MB.
    Am Heart J; 1999 Jul 16; 138(1 Pt 2):S33-8. PubMed ID: 10385789
    [Abstract] [Full Text] [Related]

  • 14. Abciximab readministration: results of the ReoPro Readministration Registry.
    Tcheng JE, Kereiakes DJ, Lincoff AM, George BS, Kleiman NS, Sane DC, Cines DB, Jordan RE, Mascelli MA, Langrall MA, Damaraju L, Schantz A, Effron MB, Braden GA.
    Circulation; 2001 Aug 21; 104(8):870-5. PubMed ID: 11514371
    [Abstract] [Full Text] [Related]

  • 15. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
    Greenbaum AB, Grines CL, Bittl JA, Becker RC, Kereiakes DJ, Gilchrist IC, Clegg J, Stankowski JE, Grogan DR, Harrington RA, Emanuelsson H, Weaver WD.
    Am Heart J; 2006 Mar 21; 151(3):689.e1-689.e10. PubMed ID: 16504633
    [Abstract] [Full Text] [Related]

  • 16. Abciximab as an adjunctive therapy for patients undergoing percutaneous coronary interventions.
    Parikh D, Juergens CP.
    Expert Opin Biol Ther; 2011 Feb 21; 11(2):235-46. PubMed ID: 21204736
    [Abstract] [Full Text] [Related]

  • 17. Intracoronary abciximab use in patients undergoing PCI at a community hospital: a single operator experience.
    Patel SS, Rana H, Mascarenhas DA.
    J Cardiovasc Pharmacol Ther; 2008 Jun 21; 13(2):89-93. PubMed ID: 18413897
    [Abstract] [Full Text] [Related]

  • 18. Incidence and time course of thrombocytopenia with abciximab and eptifibatide in patients undergoing percutaneous coronary intervention.
    Fahdi IE, Saucedo JF, Hennebry T, Ghani M, Sadanandan S, Garza-Arreola L.
    Am J Cardiol; 2004 Feb 15; 93(4):453-5. PubMed ID: 14969621
    [Abstract] [Full Text] [Related]

  • 19. Reversal of recurrent thrombocytopenia due to abciximab.
    Sharma V, Mascarenhas D.
    J Invasive Cardiol; 2004 Sep 15; 16(9):537-8. PubMed ID: 15353816
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.